Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Holding SGMO?
Track your performance easily
SGMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.29 - $1.48
Previous Close$0.83
Volume1.53M
Average Volume (3M)14.81M
Market Cap
$173.57M
Enterprise Value$174.88M
Total Cash (Recent Filing)$27.79M
Total Debt (Recent Filing)$29.10M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Oct 31, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding208,220,670
10 Day Avg. Volume3,772,594
30 Day Avg. Volume14,807,987
Standard Deviation0.32
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)7.61
Price to Sales (P/S)14.14
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.24
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$2.75Price Target Upside228.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Sangamo Biosciences News
PremiumMarket News
3 Penny Stocks to Watch Now, 8/8/24
PremiumMarket News
3 Penny Stocks to Watch Now, 7/30/24
Bulls Say, Bears Say
Bulls Say
Financial MilestonesSangamo expects to receive $50M in upfront license fees and milestones and is eligible to earn up to $1.9B in milestones, plus tiered royalties on potential net sales.
Partnerships And CollaborationsThe Genentech partnership reinforces confidence in the potential for Sangamo's zinc finger (ZF) epigenetic regulation and novel adeno-associated virus (AAV) capsid delivery platforms.
Pipeline And Clinical TrialsPositive top-line data emerged from the Phase 3 trial evaluating giroctogene fitelparvovec, a one-time gene therapy being developed in collaboration with Pfizer in hemophilia A.
Bears Say
EarningsNet loss per share was ($0.18) vs. consensus of ($0.15).
Financial PerformanceSGMO reported 4Q23 net loss of ~$60M.
Market AcceptanceWhile Roctavian, a competitive gene therapy for Hem A, has had a modest market uptake, there is still concern about market acceptance.
---
Ownership Overview
16.55% Insiders
24.38% Mutual Funds
23.45% Other Institutional Investors
35.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.29 and its highest was $1.48 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Currently, no data Available
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Aug 06, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.033.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -$0.02.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 208,220,670 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went down -13.131%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Among the largest hedge funds holding Sangamo Biosciences’s share is Wexford Capital LP. It holds Sangamo Biosciences’s shares valued at N/A.
---
Sangamo Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (228.52% Upside)
$2.75 (228.52% Upside)
Hedge Fund Trend
Decreased
By 45.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.61%
12-Months-Change
Fundamentals
Return on Equity
-194.05%
Trailing 12-Months
Asset Growth
-71.39%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q2 2024
0:00 / 0:00
---
SGMO Stock 12 Month Forecast
Average Price Target
$2.75
▲(228.52% Upside)
Technical Analysis
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+11.93%
reiterated a buy rating last month
Copying Gena Wang's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +11.93% per trade.
---